Natera, Inc. $NTRA Stake Lessened by Quantbot Technologies LP

Key Points

• Quantbot Technologies LP reduced its stake in Natera, Inc. by 29.1% during the first quarter, resulting in ownership of 3,930 shares valued at approximately $556,000.
• Institutional investors and hedge funds hold 99.90% of Natera's stock, with significant new positions acquired and stakes increased by other firms, indicating strong institutional interest.
• Natera's recent earnings report showed a revenue of $546.60 million, surpassing analyst estimates, but it reported an EPS loss of ($0.74), missing expectations.

Quantbot Technologies LP lowered its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 29.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,930 shares of the medical research company's stock after selling 1,616 shares during the period. Quantbot Technologies LP's holdings in Natera were worth $556,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Korea Investment CORP acquired a new position in shares of Natera in the first quarter worth $5,657,000. Northern Trust Corp increased its stake in shares of Natera by 1.7% in the first quarter. Northern Trust Corp now owns 712,730 shares of the medical research company's stock worth $100,787,000 after acquiring an additional 11,949 shares during the last quarter. Summit Securities Group LLC acquired a new position in shares of Natera in the first quarter worth $39,000. Corient IA LLC acquired a new position in shares of Natera in the first quarter worth $283,000. Finally, Lord Abbett & CO. LLC increased its stake in shares of Natera by 5.6% in the first quarter. Lord Abbett & CO. LLC now owns 1,521,300 shares of the medical research company's stock worth $215,127,000 after acquiring an additional 80,865 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on NTRA shares. Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Cowen reaffirmed a "buy" rating on shares of Natera in a research note on Friday, August 8th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Stephens reaffirmed an "overweight" rating and issued a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Finally, Barclays reissued an "overweight" rating and set a $210.00 target price (up from $190.00) on shares of Natera in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $193.19.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 5,807 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $132.88, for a total value of $771,634.16. Following the sale, the chief executive officer directly owned 163,593 shares of the company's stock, valued at approximately $21,738,237.84. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 2,496 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the sale, the director directly owned 5,763 shares in the company, valued at approximately $767,458.71. This represents a 30.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 58,705 shares of company stock valued at $8,743,776 in the last quarter. Insiders own 5.63% of the company's stock.

Natera Price Performance

Natera stock opened at $162.47 on Tuesday. The company has a market capitalization of $22.30 billion, a price-to-earnings ratio of -85.06 and a beta of 1.76. Natera, Inc. has a one year low of $110.57 and a one year high of $183.00. The company's fifty day moving average price is $154.73 and its two-hundred day moving average price is $153.94.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company's quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.